Brokers Issue Forecasts for PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of PTC Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings of ($2.69) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $112.00 price objective on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $437.16 million. During the same quarter in the previous year, the business earned ($1.20) earnings per share. The company's revenue was down 9.6% on a year-over-year basis.

Other analysts have also issued reports about the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Royal Bank of Canada lifted their price target on PTC Therapeutics from $57.00 to $58.00 and gave the stock an "outperform" rating in a report on Wednesday, May 7th. Wells Fargo & Company upped their price objective on PTC Therapeutics from $68.00 to $74.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Bank of America raised PTC Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $55.00 to $68.00 in a research report on Friday, May 9th. Finally, JPMorgan Chase & Co. decreased their target price on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.75.

PTC Therapeutics Trading Up 0.1%

Shares of NASDAQ PTCT traded up $0.05 during mid-day trading on Tuesday, hitting $51.74. The company had a trading volume of 827,719 shares, compared to its average volume of 869,910. The company has a market capitalization of $4.10 billion, a PE ratio of -8.71 and a beta of 0.51. PTC Therapeutics has a one year low of $28.72 and a one year high of $58.38. The firm has a 50-day simple moving average of $46.40 and a two-hundred day simple moving average of $47.96.

Insider Buying and Selling

In other PTC Therapeutics news, Director Stephanie Okey sold 5,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 8,867 shares of the company's stock, valued at approximately $478,818. The trade was a 36.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Mark Elliott Boulding sold 883 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the completion of the transaction, the vice president now directly owns 103,901 shares of the company's stock, valued at approximately $4,781,524.02. The trade was a 0.84% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,034 shares of company stock valued at $1,405,767. 5.50% of the stock is owned by company insiders.

Institutional Trading of PTC Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of PTC Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock worth $414,332,000 after acquiring an additional 53,688 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of PTC Therapeutics by 13.2% during the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock valued at $276,161,000 after buying an additional 632,049 shares during the last quarter. Toronto Dominion Bank purchased a new stake in PTC Therapeutics in the 4th quarter worth about $148,363,000. Janus Henderson Group PLC lifted its holdings in PTC Therapeutics by 24.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock valued at $105,015,000 after purchasing an additional 455,698 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of PTC Therapeutics by 45.3% during the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock valued at $77,084,000 after buying an additional 471,586 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.